Fabrication and Evaluation of Dual Peptides-Modified Liposomes Coencapsulating siRNA and Docetaxel
Combination of several approaches which facilitates the blockade of multiple disease pathways has been proven highly effective in treatment of cancer cells and their microenvironment. Combinational gene therapy and chemotherapy via cationic liposomes holds great potential since it targets therapeutic agents synergistically increasing their selective accumulation at the tumor site and enhancing their efficacy allowing administration of lower doses of each agent, thus reducing their side effects. The present protocol describes the fabrication methods to obtain the reliable stealth liposomes coencapsulating vascular endothelial growth factor (VEGF) targeting small interfering RNA (siRNA), which can inhibit angiogenesis, and chemotherapeutic docetaxel (DTX), which can kill tumor cells efficiently. Besides, two receptor-specific peptides, specifically low-density lipoprotein receptor-related protein receptor (Angiopep-2) and neuropilin-1 receptor (tLyP-1), were attached on the stealth liposomes for tumor targeting and penetration.
KeywordsDual peptides-modified liposomes Coencapsulate siRNA Docetaxel VEGF
- Gavrilov K, Saltzman WM (2012) Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 85(2):187–200Google Scholar